ALKBH3

Across TCGA pan-cancer cohorts, ALKBH3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ALKBH3 data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ALKBH3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ALKBH3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where ALKBH3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	1.000	0.897	.005	42	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.320	.014	6	view →
CCRCC	OS	Median	III,IV	0.664	0.869	.027	2	view →
LSCC	OS	Median	II,III,IV	1.000	0.886	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ALKBH3–HNSC (DFS)

Open the HNSC breakdown →